Search Videos and More
Showing 1 - 11 of 11 results
News
Upending NSCLC Survival Rates with New Care Paradigms
For years, researcher-clinician Hossein Borghaei, DO, MS, Chief, Thoracic Medical Oncology, Fox Chase Cancer Center, has been at the forefront of global exploration into the genetic, proteomics, and cellular landscape of non-small cell lung cancer (NSCLC). These efforts have led to the development of innovative clinical trials and new therapeutic paradigms.
Document
DEPARTMENT OF HEMATOLOGY/ONCOLOGY THORACIC CANCERS CLINICAL TRIALS
For general questions about clinical trials, call 215-214-1515 or visit FoxChase.org/ClinicalTrials.
Symposium
Thoracic Malignancies: A Review of the Latest Evidence
Great therapeutic strides have been made for non-small cell lung cancer (NSCLC). In this CME, renowned specialists from Fox Chase Cancer Center, Temple Lung Center, Johns Hopkins Medicine, Yale Medicine, MedStar Georgetown University Hospital, Jefferson Health, and Penn Medicine will present innovative treatment modalities that include medical, surgical and radiation oncology, pulmonology, and radiologic options.
News
LUNG CANCER PROGRAM
Comprehensive Care That Empowers Patients Through Risk Assessment, Prevention, Detection, Treatment, and Survivorship
News
Temple University Hospital and Fox Chase Cancer Center Researchers Characterize HER2 Mutations in Patients With Lung Adenocarcinoma
Human epidermal growth factor 2 (HER2) mutations can be identified in up to 6% of non-small cell lung cancer cases where KRAS, EGFR, or ALK gene mutations are also found, according to the results of research from Temple University Hospital and Fox Chase Cancer Center presented today at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
News
TAS1440 +/- All-Trans Retinoic Acid (ATRA) in Relapsed/Refractory AML
A first of its kind, Phase 1 multi-center study for Relapsed or Refractory Acute Myeloid Leukemia using an investigational drug TAS1440 by itself, and in combination with All-Trans Retinoic Acid (ATRA).
Document
Temple – Fox Chase Thoracic Surgery
The thoracic surgery program at Temple Health provides high-quality surgical care for a wide range of conditions, from benign to thoracic malignancies in the lungs, esophagus, airways, pleura, or chest wall.
News
Peritoneal Surface Malignancies
News
Immunotherapy for Never Smokers with Non-Small Cell Lung Cancer
To further evaluate the use of immunotherapy for these patients with NSCLC, Treat is serving as a primary investigator in a nationwide Phase II, double-arm, randomized clinical trial of treatment-naïve never smokers without the EGFR driver mutation and individuals with EGFR driver mutations for whom standard-of-care therapy with tyrosine kinase inhibitors have failed.
News
Pulsed Low-Dose-Rate Radiation Offers New Treatment Option for Variety of Solid Tumors
Clinicians at Fox Chase Cancer Center are exploring how an established radiation technique—pulsed low-dose-rate radiation (PLDR)—might benefit patients with a variety of solid tumors.
News
CivaSheet® for precise radiation delivery for pancreatic cancer
CivaSheet®?is an FDA-approved Pd-103 brachytherapy planar radiation source that is radioactive on only one side. It is designed to safely deliver high doses of radiation to precisely targeted areas.